Why carry out this study?

Multiple treatment options were available for managing adults with type 2 diabetes mellitus (T2DM); however, the range of options, especially oral agents, is relatively limited for children and youth with T2DM

This study evaluated the efficacy and safety of alogliptin 25 mg once daily (QD) in pediatric patients with T2DM

What was learned from the study?

Alogliptin 25 mg QD did not significantly improve glycemic control compared with placebo in pediatric patients with T2DM. This is consistent with other dipeptidyl peptidase-4 (DPP-4) inhibitors, such as sitagliptin, linagliptin, and saxagliptin, suggesting that the DPP4 inhibitor class is unlikely to be effective in treating pediatric T2DM

Alogliptin treatment was safe and well tolerated, and no new safety concerns were observed

This study provides valuable insights into the use of DPP-4 inhibitors in the pediatric population and underscores the need for continued research and exploration of various treatment approaches to better manage pediatric patients with T2DM